Anna V. Senina

818 total citations
13 papers, 157 citations indexed

About

Anna V. Senina is a scholar working on Genetics, Molecular Biology and Hematology. According to data from OpenAlex, Anna V. Senina has authored 13 papers receiving a total of 157 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 5 papers in Molecular Biology and 5 papers in Hematology. Recurrent topics in Anna V. Senina's work include Eosinophilic Disorders and Syndromes (4 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Anna V. Senina is often cited by papers focused on Eosinophilic Disorders and Syndromes (4 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Anna V. Senina collaborates with scholars based in United States, Singapore and United Kingdom. Anna V. Senina's co-authors include Zong Sheng Guo, Svetlana A. Shabalina, O. V. Matveeva, Peter M. Chumakov, Josef T. Prchal, Anthony D. Pomicter, Thomas O’Hare, Michael W. Deininger, Dongqing Yan and William L. Heaton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Anna V. Senina

12 papers receiving 152 citations

Peers

Countries citing papers authored by Anna V. Senina

Since Specialization

Citations

This map shows the geographic impact of Anna V. Senina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna V. Senina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna V. Senina more than expected).

Fields of papers citing papers by Anna V. Senina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna V. Senina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna V. Senina. The network helps show where Anna V. Senina may publish in the future.

Co-authorship network of co-authors of Anna V. Senina

This figure shows the co-authorship network connecting the top 25 collaborators of Anna V. Senina. A scholar is included among the top collaborators of Anna V. Senina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna V. Senina. Anna V. Senina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion 2018 ·Leukemia ·William L. Heaton, Anna V. Senina, Anthony D. Pomicter, Mohamed E. Salama, Phillip M. Clair, Dongqing Yan, Russell Bell, Jeremy M. Gililland, Josef T. Prchal, Thomas O’Hare, Michael W. Deininger	42
2	SIRT5 As a Therapeutic Target in Acute Myeloid Leukemia 2018 ·Blood ·Dongqing Yan, Anthony D. Pomicter, William L. Heaton, (unknown), Jonathan M. Ahmann, Anna V. Senina, (unknown), (unknown), Hein Than, Phillip M. Clair, Jamshid S. Khorashad, Thomas O’Hare, Michael W. Deininger	1
3	Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia 2017 ·Blood ·(unknown), Anthony D. Pomicter, Clinton C. Mason, Anna M. Eiring, William L. Heaton, Dongqing Yan, Anna V. Senina, Phillip M. Clair, Tessa L. Holyoake, Thomas O’Hare, Michael W. Deininger	0
4	TNFR2 Signaling Promotes Myeloproliferative Disease Progression: A Role for MAPK8? 2016 ·Blood ·William L. Heaton, Anna V. Senina, Anthony D. Pomicter, James Marvin, Josef T. Prchal, Thomas O’Hare, Michael W. Deininger	1
5	Selective Inhibition of Nuclear Cytoplasmic Transport As a New Treatment Paradigm in Myelofibrosis 2016 ·Blood ·Dongqing Yan, Srinivas K. Tantravahi, Anthony D. Pomicter, Anna V. Senina, (unknown), (unknown), Josef T. Prchal, Sabina Świerczek, Phillip M. Clair, Anna M. Eiring, Erkan Baloglu, Thomas O’Hare, Michael W. Deininger	4
6	Oncolysis by paramyxoviruses: preclinical and clinical studies 2015 ·Molecular Therapy — Oncolytics ·O. V. Matveeva, Zong Sheng Guo, (unknown), Anna V. Senina, Svetlana A. Shabalina, Peter M. Chumakov	35
7	Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm 2015 ·Experimental Hematology ·Anthony D. Pomicter, Anna M. Eiring, Anna V. Senina, Matthew S. Zabriskie, (unknown), Josef T. Prchal, Thomas O’Hare, Michael W. Deininger	6
8	Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth 2013 ·Molecular Cancer Therapeutics ·K. Mark Parnell, Jason M. Foulks, Rebecca N. Nix, (unknown), (unknown), (unknown), Anna V. Senina, (unknown), Jihua Liu, (unknown), Yong Xu, Michael A. Saunders, Xiaohui Liu, (unknown), Kevin Wright, Marc O’Reilly, Michael V. McCullar, Koc-Kan Ho, Steven B. Kanner	55
9	BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia 2013 ·Blood ·Anna M. Eiring, Ira L. Kraft, Brent D. G. Page, Tian Yi Zhang, Jamshid S. Khorashad, Nadeem A. Vellore, Kimberly R. Reynolds, Anthony D. Pomicter, Anna V. Senina, Matthew S. Zabriskie, (unknown), Clinton C. Mason, Richard Moriggl, Riccardo Baron, Thomas O’Hare, Patrick T. Gunning, Michael W. Deininger	1
10	Abstract 3762: Second generation PIM inhibitors exhibit improved activity in solid tumor models 2012 ·Cancer Research ·Jason M. Foulks, (unknown), Michael Saunders, Xiaohui Liu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ashley Chan, Li‐Wen Huang, (unknown), Anna V. Senina, Jihua Liu, Koc-Kan Ho, Michael V. McCullar, Steven B. Kanner	1
11	Abstract C200: Second-generation PIM inhibitors exhibit improved activity in solid tumor models in vitro. 2011 ·Molecular Cancer Therapeutics ·Jason M. Foulks, Yong Xu, Michael Saunders, Xiaohui Liu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ashley Chan, Li‐Wen Huang, (unknown), Anna V. Senina, Jihua Liu, (unknown), Michael V. McCullar, Steven B. Kanner	1
12	Selective in vitro and in vivo anti-tumor activity of PRLX 93936 in biological models of melanoma and ovarian cancer 2008 ·Journal of Clinical Oncology ·Sudhir Sahasrabudhe, (unknown), Michael Pierce, (unknown), (unknown), (unknown), Anna V. Senina, Robert R. Becklin, (unknown), Tracy Erkkila, Paul B. Robbins	7
13	Global DNA Hypermethylation in Chronic Lymphocytic Leukemia Correlates with Progressive Disease. 2005 ·Blood ·Margaret K. Yu, Anikó Szabó, Hector A. Bergonia, Anna V. Senina, John D. Phillips	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact